News
Why Vertex Pharmaceuticals Stock Is a Screaming Buy on the Dip
Vertex Pharmaceuticals' (NASDAQ: VRTX) remarkable momentum came to a screeching halt this week. The big biotech stock had been up well over 20% year to date. The main bad news with Vertex's Q1 results was that the company missed Wall Street's revenue and earnings estimates.
Vertex Pharmaceuticals (VRTX) stock faces a downgrade at Wolfe Research based on the company's recent lower than expected Q1 ...
In recent trading, shares of Vertex Pharmaceuticals, Inc. (Symbol: VRTX) have crossed above the average analyst 12-month target price of $509.33, changing hands for $509.47/share. When a stock ...
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be announcing earnings results tomorrow afternoon. Here’s what investors should know. Vertex Pharmaceuticals beat analysts’ revenue ...
Vertex Pharmaceuticals VRTX will release its quarterly earnings report on Monday, 2025-05-05. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Vertex ...
Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (NASDAQ: VRTX). Compared to the S&P 500 index, which is down about ...
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $475.49, marking a -1.41% move from the previous day. The stock outperformed the S&P 500, which registered a daily loss of ...
Shares of Vertex Pharmaceuticals Inc. VRTX rose 2.10% to $482.30 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 9.52% ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback